The Promise of Non-animal ‘New alternative methods’ (NAMs) in the Outsourced Pharma Industry
The Promise of Non-animal ‘New alternative methods’ (NAMs) in the Outsourced Pharma Industry
Recent regulatory changes have sparked a growing interest in non-animal 'New Alternative Methods' (NAMs), paving the way for a promising market opportunity.
Following the FDA Modernization Act 2.0, a new market opportunity has emerged for non-animal ‘New Alternative Methods’ (NAMs).
NAMs have been developed for decades in research labs and are today being introduced to the outsourced pharma industry to ‘Reduce, Refine and Replace’ (3R) animal models. These NAMs comprise many biotechnologies, ranging from 3D cell-based models such as organoids to organ-on-chip or even alternative in vivo models. The diversity of NAMs will continue to expand as new models emerge to better emulate biological system’s complexity.
According to the Organoids Society, the organoid market alone is poised to grow by 21.7% over the next three years and is estimated to reach $3.3bn in 2027. Following the same trend, the number of CRO-type providers offering NAMs boomed over the past 10 years and increased by 31.9%. There is a strong market attractiveness for NAMs as large pharmacos are now adopting and investing in these non-animal methods. Because of the complexity of biological systems, the provider landscape is highly fragmented and mainly composed of specialised players with unique technologies.
Today, the market for NAMs represents a significant investment opportunity. Collaboration between the different stakeholders will strengthen market growth going forward.
By downloading our report, you'll gain access to strategic insights on:
For further information, please reach out to Charlotte Colle or one of our other life sciences team members.
Following the FDA Modernization Act 2.0, a new market opportunity has emerged for non-animal ‘New Alternative Methods’ (NAMs).
NAMs have been developed for decades in research labs and are today being introduced to the outsourced pharma industry to ‘Reduce, Refine and Replace’ (3R) animal models. These NAMs comprise many biotechnologies, ranging from 3D cell-based models such as organoids to organ-on-chip or even alternative in vivo models. The diversity of NAMs will continue to expand as new models emerge to better emulate biological system’s complexity.
According to the Organoids Society, the organoid market alone is poised to grow by 21.7% over the next three years and is estimated to reach $3.3bn in 2027. Following the same trend, the number of CRO-type providers offering NAMs boomed over the past 10 years and increased by 31.9%. There is a strong market attractiveness for NAMs as large pharmacos are now adopting and investing in these non-animal methods. Because of the complexity of biological systems, the provider landscape is highly fragmented and mainly composed of specialised players with unique technologies.
Today, the market for NAMs represents a significant investment opportunity. Collaboration between the different stakeholders will strengthen market growth going forward.
By downloading our report, you'll gain access to strategic insights on:
- The engineering process of NAMs, emphasizing their advantages and limitations, as well as their potential application across the pharmaceutical value chain.
- Its market, including its size, drivers, and attractiveness.
- Its competitive landscape by segment and historical evolution.
- The current challenges surrounding the use of NAMs and how these could be overcome.
- Case studies of large pharmaceutical companies and CROs that have already adopted NAMs.
For further information, please reach out to Charlotte Colle or one of our other life sciences team members.